এই ওষুধে সাশ্রয় করুন
একই সক্রিয় উপাদানের অন্যান্য ব্র্যান্ড
এই ব্র্যান্ডগুলোতে একই সক্রিয় উপাদান আছে (Ribociclib). একই মাত্রা ও ধরন। বদলানোর আগে আপনার ডাক্তার বা ফার্মাসিস্টের সাথে নিশ্চিত হয়ে নিন।
ইঙ্গিত ও ব্যবহার
Riclib 200 Tablet এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
The recommended dose of Ribociclib is 600 mg taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. Ribociclib can be taken with or without food.
পার্শ্বপ্রতিক্রিয়া
Most common adverse effects (incidence >20%) are neutropenia, nausea, infections, fatigue, diarrhea, leukopenia, vomiting, alopecia, headache, constipation, rash and cough.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Interstitial Lung Disease/Pneumonitis: Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with Kisqali and other CDK4/6 inhibitors. Monitor patients for pulmonary symptoms indicative of ILD pneumonitis which may include hypoxia, cough and dyspnea.Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) can occur.QT Interval Prolongation: Kisqali has been shown to prolong the QT interval. Based on the observed QT prolongation during treatment Kisqali may require dose interruption, reduction or discontinuation. Monitor serum electrolytes (including potassium, calcium, phosphorous and magnesium) prior to the initiation of treatment at the beginning of the first 6 cycles and as clinically indicated.Increased QT Prolongation with Concomitant Use of Tamoxifen: Kisqali is not indicated for concomitant use with tamoxifen.Hepatobiliary Toxicity: Perform liver function tests (LFTs) before initiating therapy with Kisqali. Monitor LFTs every 2 weeks for first 2 cycles at the beginning of each subsequent 4 cycles and as clinically indicated. Based on the severity of the transaminase elevations, Kisqali may require dose interruption, reduction or discontinuation.Neutropenia: Perform complete blood count (CBC) before initiating therapy with Kisqali. Monitor CBC every 2 weeks for the first 2 cycles, at the beginning of each subsequent 4 cycles and as clinically indicated. Based on the severity of the neutropenia, Kisqali may require dose interruption, reduction or discontinuation.Embryo-Fetal Toxicity: Based on findings from animal studies and the mechanism of action, Kisqali can cause fetal harm when administered to a pregnant woman. Advise women of reproductive potential to use effective contraception during therapy with Kisqali and for at least 3 weeks after the last dose.
নিষেধাজ্ঞা
Ribociclib is contraindicated in patients with known hypersensitivity to this product or any of its components.